Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Natalizumab efficacy on cognitive impairment in MS.

Literature DB >> 20535512

Natalizumab efficacy on cognitive impairment in MS.

F Mattioli¹, C Stampatori, F Bellomi, R Capra.

Abstract

We report follow-up data on the efficacy of natalizumab therapy on neuropsychological impairment on an italian MS group of 39 patients at 1 year and of 11 patients at 2 years. Results show a significant reduction in relapse rate, in the number of impaired neuropsychological tests as well as in several single executive function and reasoning tests scores at 1 year. Improvement persisted at 2 years, including also memory and speed processing tasks. These data support the efficacy of natalizumab therapy in all the clinical domains, including cognitive deterioration, in multiple sclerosis patients.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2011 PMID： 20535512 DOI： 10.1007/s10072-010-0351-0

Source DB: PubMed Journal: Neurol Sci ISSN： 1590-1874 Impact factor: 3.307

11 in total

1. A simple objective technique for measuring flexibility in thinking.

Authors: E A BERG
Journal: J Gen Psychol Date: 1948-07

Review 2. Cognitive impairment in multiple sclerosis.

Authors: F Patti
Journal: Mult Scler Date: 2008-09-19 Impact factor: 6.312

3. Paced auditory serial-addition task: a measure of recovery from concussion.

Authors: D M Gronwall
Journal: Percept Mot Skills Date: 1977-04

Review 4. [Italian standardization and classification of Neuropsychological tests. The Italian Group on the Neuropsychological Study of Aging].

Authors:
Journal: Ital J Neurol Sci Date: 1987-12

Review 5. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

Authors: Richard A Rudick; Alfred Sandrock
Journal: Expert Rev Neurother Date: 2004-07 Impact factor: 4.618

6. Efficacy and specificity of intensive cognitive rehabilitation of attention and executive functions in multiple sclerosis.

Authors: Flavia Mattioli; Mattioli Flavia; Chiara Stampatori; Deborah Zanotti; Giovanni Parrinello; Ruggero Capra
Journal: J Neurol Sci Date: 2009-10-13 Impact factor: 3.181

7. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.

Authors: Eva Havrdova; Steven Galetta; Michael Hutchinson; Dusan Stefoski; David Bates; Chris H Polman; Paul W O'Connor; Gavin Giovannoni; J Theodore Phillips; Fred D Lublin; Amy Pace; Richard Kim; Robert Hyde
Journal: Lancet Neurol Date: 2009-02-07 Impact factor: 44.182

8. Health-related quality of life in multiple sclerosis: effects of natalizumab.

Authors: Richard A Rudick; Deborah Miller; Steve Hass; Michael Hutchinson; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Gavin Giovannoni; Eva Havrdova; Ludwig Kappos; Fred D Lublin; David H Miller; Paul W O'Connor; J Theodore Phillips; Chris H Polman; Ernst-Wilhelm Radue; William H Stuart; Andrzej Wajgt; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara
Journal: Ann Neurol Date: 2007-10 Impact factor: 10.422

Review 9. Cognitive impairment in multiple sclerosis.

Authors: Nancy D Chiaravalloti; John DeLuca
Journal: Lancet Neurol Date: 2008-12 Impact factor: 44.182

10. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Authors: Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal: N Engl J Med Date: 2006-03-02 Impact factor: 91.245

8 in total

1. Changes in Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Treated with Natalizumab: The ENER-G Study.

Authors: Jeffrey Wilken; Robert L Kane; Cynthia L Sullivan; Mark Gudesblatt; Sylvia Lucas; Robert Fallis; Xiaojun You; Pam Foulds
Journal: Int J MS Care Date: 2013

2. White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.

Authors: O T Wiebenga; M M Schoonheim; H E Hulst; G J A Nagtegaal; E M M Strijbis; M D Steenwijk; C H Polman; P J W Pouwels; F Barkhof; J J G Geurts
Journal: AJNR Am J Neuroradiol Date: 2016-03-10 Impact factor: 3.825

3. Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results.

Authors: Ruggero Capra; Vincenzo Brescia Morra; Massimiliano Mirabella; Claudio Gasperini; Cinzia Scandellari; Rocco Totaro; Nicola De Rossi; Silvia Masera; Valentina Zipoli; Francesco Patti
Journal: Neurol Sci Date: 2020-11-17 Impact factor: 3.307

4. Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.

Authors: Pietro Iaffaldano; Rosa Gemma Viterbo; Damiano Paolicelli; Guglielmo Lucchese; Emilio Portaccio; Benedetta Goretti; Vita Direnzo; Mariangela D'Onghia; Stefano Zoccolella; Maria Pia Amato; Maria Trojano
Journal: PLoS One Date: 2012-04-25 Impact factor: 3.240

5. Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.

Authors: Flavia Mattioli; Chiara Stampatori; Fabio Bellomi; Cristina Scarpazza; Ruggero Capra
Journal: PLoS One Date: 2015-07-06 Impact factor: 3.240